{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:05:43Z","timestamp":1742385943999},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"DOI":"10.2146\/ajhp150336","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T10:18:35Z","timestamp":1458555515000},"page":"463-467","source":"Crossref","is-referenced-by-count":2,"title":["Implementation of a new dantrolene formulation across a multifacility health system"],"prefix":"10.1093","volume":"73","author":[{"given":"Chelsea M.","family":"Zavilla","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Pharmacy, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Skledar","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center Health System, Pittsburgh, PA, and University of Pittsburgh School of Pharmacy, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Beth","family":"Lang","sequence":"additional","affiliation":[{"name":"H.C. Pharmacy, Inc., Pittsburgh, PA, and University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Gross","sequence":"additional","affiliation":[{"name":"Pharmacy, Inc., Pittsburgh, PA, and University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041102504236300_b1-0730463","unstructured":"Eagle Pharmaceuticals Inc. New option for the treatment of malignant hyperthermia (MH). Ryanodex (dantrolene sodium) for injectable suspension (August 2014). www.ryanodex.com\/wp-content\/uploads\/2014\/09\/ryanodex-mh-white-paper.pdf (accessed 2015 Mar 8)."},{"key":"key\n\t\t\t\t2019041102504236300_b2-0730463","unstructured":"Malignant Hyperthermia Association of the United States. FAQs: general MH questions. www.mhaus.org\/faqs\/about-mh (accessed 2015 Mar 9)."},{"key":"key\n\t\t\t\t2019041102504236300_b3-0730463","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1213\/ANE.0b013e3181c6b9b2","article-title":"Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006","volume":"110","author":"Larach","year":"2010","journal-title":"Anesth Analg"},{"key":"key\n\t\t\t\t2019041102504236300_b4-0730463","unstructured":"Malignant Hyperthermia Association of the United States. FAQs: dantrolene. www.mhaus.org\/faqs\/dantrolene (accessed 2015 Mar 9)."},{"key":"key\n\t\t\t\t2019041102504236300_b5-0730463","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/EJA.0b013e3283439545","article-title":"Comparison of the therapeutic effectiveness of a dantrolene sodium solution and a novel nanocrystalline suspension of dantrolene sodium in malignant hyperthermia normal and susceptible pigs","volume":"28","author":"Sch\u00fctte","year":"2011","journal-title":"Eur J Anaesthesiol"},{"key":"key\n\t\t\t\t2019041102504236300_b6-0730463","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1213\/ANE.0b013e3182937d8b","article-title":"Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands","volume":"118","author":"Riazi","year":"2014","journal-title":"Anesth Analg"},{"key":"key\n\t\t\t\t2019041102504236300_b7-0730463","unstructured":"Malignant Hyperthermia Association of the United States. What is MH? (March01, 2015). www.mhaus.org (accessed 2015 Mar 26)."},{"key":"key\n\t\t\t\t2019041102504236300_b8-0730463","unstructured":"Eagle Pharmaceuticals Inc. FDA grants seven years\u2019 market exclusivity to Eagle Pharmaceuticals\u2019 Ryanodex for the treatment of malignant hyperthermia (February23, 2015). www.investor.eagleus.com\/press-release\/fda-grants-seven-years-market-exclusivity-eagle-pharmaceuticals-ryanodex-treatment-mal (accessed 2015 Mar 25)."},{"key":"key\n\t\t\t\t2019041102504236300_b9-0730463","unstructured":"US WorldMeds LLC. Revonto (dantrolene sodium for injection): frequently asked questions. www.revonto.com\/faqs.asp (accessed 2015 Mar 10)."},{"key":"key\n\t\t\t\t2019041102504236300_b10-0730463","unstructured":"Eagle Pharmaceuticals Inc. Ryanodex (dantrolene sodium) for injectable suspension. Frequently asked questions. www.ryanodex.com\/resources\/faqs (accessed 2015 Mar 10)."},{"key":"key\n\t\t\t\t2019041102504236300_b11-0730463","unstructured":"Healing the Children. Welcome to the national organization of Healing the Children. www.healingthechildren.org (accessed 2015 Mar 26)."},{"key":"key\n\t\t\t\t2019041102504236300_b12-0730463","unstructured":"Peter M. Winter Institute for Simulation, Education, and Research of University of Pittsburgh Medical Center. WISER: 20 years of simulation improving healthcare. www.wiser.pitt.edu (accessed 2015 Mar 26)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/73\/7\/463\/28335070\/ajhp0463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T13:00:12Z","timestamp":1600347612000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/73\/7\/463\/5101765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,1]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp150336","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,4,1]]},"published":{"date-parts":[[2016,4,1]]}}}